# Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

- Link: https://www.thailand-business-news.com/pr-news/dayspring-pharma-announces-positive-topline-results-from-phase-ii-clinical-trial-of-cg2001-for-the-treatment-of-androgenetic-alopecia-aga
- Published: 2026-06-08T08:28:00+07:00
- Author: PR Newswire

SEOUL, South Korea, June 8, 2026 /PRNewswire/ — **Dayspring Pharma, a clinical-stage
biotechnology company focused on innovative dermatology therapies, announced the
first public disclosure of positive topline results from its Phase II randomized,
double-blind, placebo-controlled trial of CG2001 at the 14th World Congress for 
Hair Research (WCHR) in Seoul, South Korea. The results were presented orally by
Professor Cheng Zhou, Director of the Department of Dermatology at Peking University
People’s Hospital.**

[⌊Professor Cheng Zhou presents the efficacy and safety results of CG2001, a topical
combination of minoxidil and finasteride, at the 14th World Congress for Hair Research
in Seoul, South Korea⌉⌊Professor Cheng Zhou presents the efficacy and safety results
of CG2001, a topical combination of minoxidil and finasteride, at the 14th World
Congress for Hair Research in Seoul, South Korea⌉[
Professor Cheng Zhou presents
the efficacy and safety results of CG2001, a topical combination of minoxidil and
finasteride, at the 14th World Congress for Hair Research in Seoul, South Korea

CG2001 is a topical fixed-dose combination formulation containing minoxidil and 
finasteride, being evaluated for the treatment of male androgenetic alopecia.

The trial consisted of the following treatment arms: CG2001 (5% Minoxidil and 0.075%
Finasteride) once daily (QD); CG2001 (5% Minoxidil and 0.1% Finasteride) once daily(
QD); CG2001 (5% Minoxidil and 0.075% Finasteride) twice daily (BID); and a Control
Group.

**The study met its primary endpoint: at Week 24, the group treated with CG2001 (
5% Minoxidil and 0.075% Finasteride) twice daily demonstrated a statistically significant
improvement in the change from baseline in Target Area Hair Count (TAHC) compared
to the placebo group.** Additionally, favorable safety and tolerability results 
were observed.

**Key topline results include:**

 ◦ **At Week 24, the group treated with CG2001 (5% Minoxidil and 0.075% Finasteride)
   twice daily achieved an increase of 28.17 hairs/cm² from baseline in TAHC (p=
   0.006), a key efficacy metric, outperforming the placebo group, which showed 
   an increase of 7.68 hairs/cm². **
 ◦ In the CG2001 (Minoxidil 5% and Finasteride 0.075%) twice-daily group, a trend
   of sustained increase in ΔTAHC was observed at Weeks 6, 12, 18, and 24.
 ◦ In the CG2001 (Minoxidil 5% and Finasteride 0.075%) twice-daily group a trend
   toward improvement in subject self-assessments, were also observed.
 ◦ CG2001 was generally well-tolerated across all treatment groups, and no sex related
   adverse event were identified.
 ◦ All adverse events were mild to moderate in severity.

"Despite approved treatment options, androgenetic alopecia remains an area of significant
unmet medical need. We are encouraged by the Phase II results, which support CG2001’
s potential as a differentiated treatment option and its continued clinical development,"
said Baohui Yu, CEO of Dayspring Pharma.

Dayspring Pharma is currently engaging with regulatory authorities to define the
next phase of clinical development.

**About CG2001CG2001 is a topical combination of minoxidil and finasteride developed
to harness the synergistic potential of two cornerstone therapies for AGA. Both 
are widely recognized as first-line treatments for male pattern hair loss: minoxidil
promotes hair growth, while finasteride inhibits 5α-reductase and reduces dihydrotestosterone
levels.

CG2001 is formulated as a specifically designed foam with an optimized dose ratio
and delivery system to improve local follicular delivery, enhance efficacy, and 
minimize systemic exposure associated with oral finasteride.

**About Dayspring Pharma**

Dayspring Pharma is a pharmaceutical company focused on innovation in dermatology
and hair health. The company develops differentiated therapies to address unmet 
clinical needs. For more information, please visit [dayspringpharma.com](https://dayspringpharma.com/).

**Contact:** Dayspring Pharma, [chenguang@dayspringpharma.com](https://www.thailand-business-news.com/pr-news/chenguang@dayspringpharma.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA) ](http://www.prnasia.com/story/archive/4973662_AE73662_0?rand=184833)